Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan and Aspirin DDI Study in Healthy Male Volunteers
NCT07853248Phase 1Not yet recruiting
- Sponsor
- HK inno.N Corporation
- Start
- Oct 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegoprazan in gastroesophageal reflux disease (GERD), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Steady-State Plasma Concentration of Aspirin, Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Steady State of Aspirin and 4 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07853248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07853248.